Highest-materiality recent filing
Windtree Therapeutics President and COO Eric Curtis resigns effective immediately
Eric L. Curtis resigned as President and COO effective January 5, 2026.
Windtree issues $857K convertible note due 2026 to fund CommLoan acquisition advance
Issued $857,142.86 in senior convertible notes to an institutional investor; interest 10% per annum, maturity Nov 26, 2026.
Issued $1.6M aggregate principal in senior convertible promissory notes due Oct 9, 2026 to institutional investors.
Windtree Therapeutics CMO Dr. Steven Simonson resigns effective immediately
Steven G. Simonson, M.D., resigned as SVP and Chief Medical Officer on Sept. 2, 2025.
Windtree shareholders approve 1:2-1:25 reverse split, 8x authorized share increase, all 9 proposals
All 9 proposals passed at Aug 28 special meeting; majority of votes cast in favor.
Windtree Therapeutics receives Nasdaq delisting notice; stock to trade OTC Aug 21
Nasdaq notified Windtree of delisting due to noncompliance with Listing Rule 5550(a)(2) (minimum bid price).
Windtree terminates SEISMiC-C study of istaroxime after 20 enrollments; cites limited resources
Terminated Phase 2 SEISMiC-C trial (istaxime for cardiogenic SCAI Stage C) at 20 enrollments.
Interim analysis of first 20 patients in SEISMiC C Phase 2 study: no new safety signals, hemodynamic improvements consistent with prior trials.
Windtree secures up to $520M for BNB crypto treasury; 99% of proceeds to buy BNB
Entered Common Stock Purchase Agreement for up to $500M equity line; additional $20M agreement with Build and Build Corp.
Windtree raises up to $200M for BNB crypto treasury strategy, shifting from biotech
Entered $60M securities purchase agreement (upsizable to $200M) led by Build and Build Corp for Series E Preferred Stock and Warrants.
Windtree terminates $3M earnest money real estate deal; CFO resigns; raises $150K
On June 24, 2025, Windtree terminated the Purchase Agreement for the Aubrey property; TBB CPD demands $3M earnest money; company disputes.
Nasdaq notified Windtree on June 18, 2025 that closing bid price has been below $1.00 for 30 consecutive days.
Raised $3.1M from DFU convertible note and $800K from other investors; proceeds to retire Titan debt and fund operations.
Windtree Q1 operating loss $4.1M, cash through May 2025; pivots to revenue via real estate
Operating loss $4.1M vs $4.4M prior year; net loss $5.0M ($4.63/share) vs net income $10.2M in Q1 2024.
WINT LLC (subsidiary) assigned rights to buy property; advanced $1.4M earnest money to extend closing to May 23, 2025.
Windtree raises $2.5M via Series D convertible preferred at $1.368/share conversion price
Private placement of 3,125 Series D convertible preferred shares for aggregate gross proceeds of approximately $2.5 million.
Windtree Therapeutics FY2024 net loss $1.8M; cash $1.8M; pivots to revenue-generating acquisitions
Net loss $1.8M vs $20.3M in 2023; loss per basic share $104.35 on $5.5M net loss attributable to common.
Windtree raises $250K via secured notes, licenses Phexxi supply rights, regains Nasdaq compliance
Issued $312,500 principal in senior secured notes at 10% interest, due March 2026, with 20% OID; net proceeds $250,000.
Approximately 1,895 Series C Preferred shares converted into 11,792,305 common shares at reduced conversion price of $0.1608.
Windtree shareholders approve reverse stock split, reject equity plan increase
Reverse split approved (ratio 1:5 to 1:50, board discretion) with 2,504,535 for, 1,752,258 against.
Company offered Series C preferred holders conversion price cut to $0.1608; accept by Jan 31, 2025.
Windtree appoints Leanne Kelly to board; launches strategy to acquire small biotechs with equity
Leanne Kelly appointed as independent director and Audit Committee chair effective Jan 8, 2025.
Windtree shifts strategy to acquire FDA-approved product companies via all-stock deals
New corporate strategy targets acquisition of small companies with FDA-approved products using equity.
Windtree receives Nasdaq delisting notices for board independence and bid price deficiencies
CEO appointment Jed Latkin (former independent director) on Dec 1, 2024 caused loss of majority independent board and audit committee shortfall.
Windtree engages New Growth Advisors to explore strategic options for cardiovascular portfolio
Engaged New Growth Advisors to lead out-licensing or asset sale process for istaroxime and oral SERCA2a activators.
Windtree reports Q3 net loss $3.8M; cash runway only through Jan 2025
Operating loss $4.7M flat vs Q3 2023; net loss $3.8M ($4.23/share) vs $4.4M ($15.47/share) a year ago.
Windtree CEO Craig Fraser retires; Jed Latkin appointed President & CEO effective Dec 1, 2024
Craig Fraser retires as President and CEO effective Dec 1, 2024, but remains Chairman of the Board.
Windtree Therapeutics share count more than doubles to 3.68M in three weeks
From Sep 14 to Oct 4, sold 790,500 shares via ELOC for $1.7M gross proceeds.
Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock
Primary endpoint met: istaroxime significantly improved systolic blood pressure (SBP AUC) vs placebo (p=0.0070) in combined Part A/B analysis.
Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock
Istaroxime met primary endpoint: significantly improved systolic blood pressure profile over six hours vs placebo.
Sold 949,948 common shares under ELOC for ~$3.2M gross proceeds as of Sep 13, 2024.
Windtree Q2 net loss $12M ($20.91/shr), istaroxime data expected Q3 2024
Net loss of $12.0M ($20.91 per share) on 0.6M shares; operating loss $11.5M vs. $6.8M in Q2 2023.
Windtree raises ~$1.0M via Series C preferred stock and warrants; exercise price $4.11
Private placement of 1,250 Series C Convertible Preferred Shares and warrants for 267,380 common shares.
Windtree Therapeutics raises $12.9M via Series C Preferred and Warrants; cancels $9.5M debt
Gross proceeds of ~$12.9M from private placement of Series C Convertible Preferred Stock and warrants; $9.5M used to cancel existing convertible notes, secured notes, and Series B preferred shares.
Windtree enters $35M equity line, issues $350K convertible note and $405K bridge notes
Common Stock Purchase Agreement with Seven Knots, LLC allows sales up to $35M (or 19.99% outstanding) over 36 months at up to 5% discount to VWAP.
On April 17, 2025, Mr. Fraser notified the Windtree Therapeutics, Inc.(the “ Company ”) Board of Directors (the “ Board ”) of his resignation from the Board, effective immediately.
On January 8, 2025, the Board of Directors (the "Board") of Windtree Therapeutics, Inc. (the "Company") approved an increase in the number of directors on the Board to five and appointed Leanne Kelly as a director and member and chair of the Audit Committee, effective immediately.
Craig Fraser will retire as the Company’s President and Chief Executive Officer, effective as of December 1, 2024
the Company announced the appointment of Jed Latkin, age 50, a current member of the Board, to serve as the Company’s President and Chief Executive Officer, effective as of the Transition Date.
On September 25, 2024, the board of directors (the “ Board ”) of Windtree Therapeutics, Inc. (the “ Company ”) appointed Jamie McAndrew as Senior Vice President and Chief Financial Officer, effective as of September 25, 2024 (the “ Effective Date ”).
On August 13, 2024, the Board appointed Jed Latkin and Saundra Pelletier to fill the vacancies created by the resignation of Mr. Geffken and Ms. Williams, effective August 13, 2024.
On August 13, 2024, Daniel Geffken and Leslie J. Williams each notified Windtree Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), including all committees of the Board on which he or she serves, effective August 13, 2024.
On August 13, 2024, Daniel Geffken and Leslie J. Williams each notified Windtree Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), including all committees of the Board on which he or she serves, effective August 13, 2024.
On August 13, 2024, the Board appointed Jed Latkin and Saundra Pelletier to fill the vacancies created by the resignation of Mr. Geffken and Ms. Williams, effective August 13, 2024.
Max materiality 1.00 · Median 0.65 · Most common event other_material